<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420327</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00057097</org_study_id>
    <nct_id>NCT02420327</nct_id>
  </id_info>
  <brief_title>Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine</brief_title>
  <acronym>GalaNic</acronym>
  <official_title>The Use of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine
      can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's
      disease. This proof-of-principle study is performed in healthy non-smokers and involves two
      single exposures to a nicotine patch (7 mg/24 hrs) and two single exposures to galantamine (4
      mg). The dose of galantamine is substantially lower than the clinical dose range of 16-24
      mg/day. The hypothesis is that performance-enhancing effects of nicotine are greater in the
      presence of this low dose of galantamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy non-smokers will be screened for study eligibility and receive training on three
      different attention tasks. Over four test session, participants will then perform these tasks
      after receiving (1) a placebo patch and a placebo capsule, (2) a nicotine patch (7 mg/24 hrs)
      and a placebo capsule, (3) a placebo patch and a galantamine capsule, and (4) a nicotine
      patch and a galantamine capsule. The four test session are performed on separate days and
      take approximately 7 hours each. During the first 5 hours, the participant may read or watch
      TV while nicotine and/or galantamine are being absorbed. During the last two hours, the
      participant will perform the attention tasks on a computer. The investigators hypothesize
      that performance-enhancing effects of nicotine, which were documented in previous research,
      will be larger in the presence than in the absence of galantamine. This proof-of-concept
      would have implications for the development of drugs for the treatment of conditions such as
      Alzheimer's disease or schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spatial Attentional Resource Allocation Task</measure>
    <time_frame>45 min</time_frame>
    <description>The task requires detecting brief stimuli presented at random locations on the screen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Visual Information Processing Task</measure>
    <time_frame>30 min</time_frame>
    <description>The task requires following a stream of digits and detecting three consecutive odd or even numbers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Detection Task</measure>
    <time_frame>15 min</time_frame>
    <description>The task requires encoding the color of 1 or 5 shape items and detecting a color change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood Scale</measure>
    <time_frame>5 min x 7</time_frame>
    <description>Participants rate their current subjective state on a list of adjectives.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor</condition>
  <arm_group>
    <arm_group_label>placebo + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive a patch and a capsule, neither of which contain any drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a patch containing nicotine (7 mg/24 hrs) and a capsule not containing any drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + galantamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a patch not containing any drug and a capsule containing 4 mg of galantamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine + galantamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a patch containing nicotine (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>nicotine patch (7 mg/24 hrs)</description>
    <arm_group_label>nicotine + placebo</arm_group_label>
    <arm_group_label>nicotine + galantamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>galantamine capsule (4 mg)</description>
    <arm_group_label>placebo + galantamine</arm_group_label>
    <arm_group_label>nicotine + galantamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Patch</description>
    <arm_group_label>placebo + placebo</arm_group_label>
    <arm_group_label>placebo + galantamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>placebo + placebo</arm_group_label>
    <arm_group_label>nicotine + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 21 to 55 years.

          -  No exposure to any nicotine-containing product in the last year.

          -  Smoked no more that 40 cigarettes, cigars or cigarillos in lifetime.

          -  Normal or corrected to normal vision (at least 20/80).

          -  Body weight 110-220 lbs.

        Exclusion Criteria:

          -  Pregnant or breast-feeding.

          -  Drug or alcohol abuse or dependence currently or in the last 2 years.

          -  DSM Axis I mood, anxiety or psychotic disorder.

          -  Cardiovascular or cerebrovascular disease, such as history of myocardial infarction
             and ischemia, heart failure, angina, stroke, severe arrhythmias, or EKG abnormalities
             (Wolf-Parkinson-White syndrome, Complete left bundle branch block, PR interval &lt;120 ms
             or &gt;200 ms, Prolonged QT interval (corrected) &gt;500 ms, Cardiac arrhythmias as defined
             by PACs &gt;3 per min or PVCs &gt;1 per min).

          -  Uncontrolled hypertension (resting systolic BP above 140 or diastolic above 90 mm Hg).

          -  Hypotension (resting systolic BP below 90 or diastolic below 60).

          -  Significant kidney or liver impairment.

          -  Moderate to severe asthma.

          -  Obstructive pulmonary disease.

          -  Type I or II diabetes.

          -  Use of any centrally active medications; any peripherally acting cholinergic
             medications; cimetidine; ketoconazole; erythromycin; quinidine, or chronic
             nonsteroidal anti-inflammatory drugs.

          -  History of or current neurological illnesses, such as stroke, seizure disorders,
             neurodegenerative diseases, or organic brain syndrome.

          -  Learning disability, mental retardation, or any other condition that impedes
             cognition.

          -  Heart rate &lt;55 bpm.

          -  Current or history of gastric ulcer disease.

          -  Any surgeries requiring full anesthesia scheduled within 2 weeks of any of the study
             test sessions.

          -  Anemia.

          -  Inability to perform the Rapid Visual Information Processing Task.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britta Hahn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland School of Medicine, Maryland Psychiatric Research Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Britta Hahn</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>galantamine</keyword>
  <keyword>attention</keyword>
  <keyword>cognition</keyword>
  <keyword>non-smoker</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

